ModifiedQualChoicePolicy CP.MP.142

Urinary Incontinence Devices and Treatments

Customize your policy alerts

Sign up for QualChoice Policy CP.MP.142 alerts

Get alerted when Policy CP.MP.142 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Defines medical necessity criteria and coding guidance for sacral neuromodulation (SNS/SNM) and urethral bulking agents (UBA) for treating lower urinary tract dysfunction and stress urinary incontinence for QualChoice members/enrollees.

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

ModifiedQualChoicePolicy CP.MP.142

Urinary Incontinence Devices and Treatments

Customize your policy alerts

Sign up for QualChoice Policy CP.MP.142 alerts

Get alerted when Policy CP.MP.142 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerQualChoice

PolicyUrinary Incontinence Devices and Treatments

Policy CodePolicy CP.MP.142

Change TypeMaterial clinical and operational updates

Effective Date

Next Review Date

Key ActionObtain prior authorization and document ≥6 months of symptoms, failure of required conservative therapies, and a percutaneous stimulation test showing ≥50% improvement before permanent SNM implantation.

SourceLink

POLICY UPDATE CHANGES

Added HCPCS code A4290.

Criteria I.D. #1 was updated to include continence-support pessaries as a conservative measure, later removed.

Updated Criteria I.B. time threshold for urinary retention from at least 12 months to at least 6 months.

Added language to Criteria I. and II. regarding use of a United States Food and Drug Administration (FDA) approved device and clarified that an FDA approved device is included in Criteria II.

Updated verbiage in Criteria II.B. to state 'at least' a 50% reduction in incontinence.

Reworded Criteria III.B. for flow and changed Kegel exercises to pelvic floor therapy; changed 'patient' to 'Member/enrollee' in Criteria III.C.

Added note under Description to refer to CP.MP.133 Posterior Tibial Nerve Stimulation for Voiding Dysfunction for posterior tibial nerve stimulation treatment for urinary incontinence.

Changed review date header labels (e.g., 'review date' to 'date of last revision') and other minor formatting/wording edits.

50%required stimulation test response

>=6msymptom duration prior to SNM trial

FDA-listednamed bulking agents

A4290HCPCS code added

CPT/HCPCScoding included

Coverage Criteria and Medical Necessity

Sacral neuromodulation (trial) — Medical necessity

Covered when ALL of the following are met:

SNM trial criteria: A. Diagnosis is non-obstructive urinary retention or overactive bladder; B. Symptoms of incontinence, urgency/frequency, or urinary retention have been present for at least six months and have resulted in significant disability (e.g., limited ability to work or participate in activities outside the home); C. Symptoms are not related to a neurologic condition; D. Failure of conservative measures: (1) For urgency/frequency or incontinence: bladder training, pelvic floor physical therapy with biofeedback, and pharmacologic treatment; (2) For non-obstructive urinary retention: intermittent self-catheterization, unless not well-tolerated, and pharmacologic treatment.

All conditions A-D must be met prior to trial.

Permanent SNM implantation — Medical necessity

Covered when BOTH of the following are met:

Permanent SNM criteria: A. Criteria in the SNM trial section are met; B. A percutaneous stimulation test provided at least a 50% reduction in incontinence, retention, or urgency/frequency symptoms prior to permanent device implantation.50% improvement required

Both A and B required.

Urethral bulking agent injection — Medical necessity

Covered when ALL of the following are met:

UBA criteria: A. Diagnosis of persistent or recurrent stress urinary incontinence due to one of the following: (1) intrinsic sphincter deficiency; (2) post-bladder support surgery; (3) post-traumatic or surgical injury; B. Failure of conservative management such as pelvic floor therapy, biofeedback, electrical stimulation, and pharmacotherapies; C. Member/enrollee is unable to tolerate surgery or does not wish to have surgery.

All A-C required for UBA coverage.

UBA experimental/insufficient evidence

Not supported uses: There is insufficient evidence in the published peer-reviewed literature to support use of autologous fat injections, non-FDA approved procedures, and any other circumstances not specified in the medically necessary criteria.

These uses are considered unsupported by current literature.

High-level Criteria Sections

Policy contains multiple criteria sections (I, II, III) with device- and therapy-specific requirements and thresholds.

Criteria I: Includes requirement or reference to United States FDA-approved device where specified; includes timing for urinary retention (at least 6 months) in I.B.urinary retention >= 6 months

See full policy for complete subcriteria

Criteria II: Includes requirement to demonstrate at least a 50% reduction in incontinence (Criteria II.B.) and may require an FDA-approved device for certain treatments.>=50% reduction

See full policy for complete subcriteria

Criteria III: Contains requirements referencing pelvic floor therapy (replacing Kegel exercises) and terminology changes to 'Member/enrollee'.

See full policy for complete subcriteria

Injection of autologous fat for periurethral bulking and urethral bulking procedures that are not United States FDA–approved are not supported by this policy. The policy states there is insufficient evidence in the published peer‑reviewed literature to support use of autologous fat injections and non‑FDA approved urethral bulking procedures for stress urinary incontinence, and these uses are therefore excluded from coverage.

Urethral bulking agent (UBA) injections are limited to the indications and products explicitly supported by the policy — namely United States FDA‑approved periurethral bulking agents for persistent or recurrent stress urinary incontinence after failed conservative management. Use of UBAs outside those specified circumstances, including injection of autologous fat or procedures that lack FDA approval, are considered unsupported due to insufficient peer‑reviewed evidence and are not recommended for coverage.

UBA applications beyond the stated indications — for example novel or experimental injectables such as autologous skeletal muscle or fat preparations, or other non‑FDA‑cleared techniques — are regarded as investigational/unsupported. The policy notes that additional peer‑reviewed studies are necessary to confirm efficacy of such approaches prior to considering them medically necessary.

Specifically, UBA injection of autologous fat and other non‑FDA approved procedures are identified in the policy as having insufficient evidence to support their use. The document highlights concerns about efficacy and the need for repeat treatments with some bulking agents, and it explicitly excludes autologous fat and non‑FDA‑approved techniques from supported indications.

Procedure, Supply, and Billing Codes

Covered CPT CodesCPTCovered

51715	Endoscopic injection of implant material into the submucosal tissue of the urethra and/or bladder neck.
64561	Percutaneous implantation of neurostimulator electrode array; sacral nerve (transforaminal placement) including image guidance, if performed.
64581	Open implantation of neurostimulator electrode array; sacral nerve (transforaminal placement).
64585	Revision or removal of peripheral neurostimulator electrode array.
64590	Insertion or replacement of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver.
64595	Revision or removal of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, with detachable connection to electrode array.

Covered HCPCS CodesHCPCSCovered

A4290	Sacral nerve stimulation test lead, each.
L8603	Injectable bulking agent, collagen implant, urinary tract, 2.5 ml syringe, includes shipping and necessary supplies.
L8606	Injectable bulking agent, synthetic implant, urinary tract, 1 ml syringe, includes shipping and necessary supplies.
L8679	Implantable neurostimulator, pulse generator, any type.
L8680	Implantable neurostimulator electrode, each.
L8681	Patient programmer (external) for use with implantable programmable neurostimulator pulse generator, replacement only.
L8682	Implantable neurostimulator radiofrequency receiver.
L8683	Radiofrequency transmitter (external) for use with implantable neurostimulator radiofrequency receiver.
L8684	Radiofrequency transmitter (external) for use with implantable sacral root neurostimulator receiver for bowel and bladder management, replacement.
L8685	Implantable neurostimulator pulse generator, single array, rechargeable, includes extension.

1–10 of 14

1/2

Policy-added HCPCSHCPCS

A4290

Added HCPCS code A4290

Percutaneous stimulation test response

RequirementPercutaneous stimulation test must demonstrate at least a 50% reduction in incontinence, retention, or urgency/frequency symptoms before permanent SNM implantation.

ContextThis threshold is specified in Criteria II.B. as a condition for permanent sacral neuromodulation placement.

Denial riskFailure to document >=50% symptom reduction on the percutaneous test may trigger denial of permanent SNM implantation.

Symptom duration before SNM trial

Minimum durationSymptoms (incontinence, urgency/frequency, or urinary retention) must have been present for at least 6 months prior to an SNM trial.

Provider Requirements, Prior Authorization, and Documentation

Prior Authorization

Prior authorization required for SNM and UBA procedures/supplies

Submit prior authorization per usual payer processes for sacral neuromodulation (SNM) procedures and urethral bulking agent injections, including SNM trial/implantation, generator/electrode insertion, revisions, and removals, and associated supplies.

CPT codes: 51715, 64561, 64581, 64585, 64590, 64595
HCPCS/supply codes: A4290, L8603, L8606, L8679–L8689

Prior Authorization

Prior authorization implied for covered devices/treatments (A4290 may require review)

Prior authorization is implied for services addressed by this clinical policy; added HCPCS code A4290 (sacral nerve stimulation test lead) may require review consistent with the policy criteria and FDA‑approval language referenced in Criteria I and II.

A4290 is listed in the coding section as 'Sacral nerve stimulation test lead, each' and was added to the policy coding.
Review should ensure services meet the specified criteria (e.g., FDA‑approved device where required).

Background and Clinical Context

Sacral neuromodulation (SNM) delivers implantable electrical stimulation to the sacral nerve roots (typically S3) to treat lower urinary tract dysfunction. Clinical use includes an initial temporary test stimulation to assess symptom response; if the test provides adequate benefit, a permanent implantable neurostimulator and lead are placed. The policy requires objective documentation of diagnosis, prior conservative therapies, symptom duration (commonly ≥ 6 months where specified), and a successful percutaneous stimulation test demonstrating at least a 50% reduction in incontinence, retention, or urgency/frequency symptoms prior to permanent implantation.

Key Definitions

Sacral neuromodulation (SNM)

DefinitionSacral neuromodulation (SNM) or sacral nerve stimulation (SNS) is stimulation of nerves that innervate the bladder and pelvic floor to treat lower urinary tract dysfunction; it involves a temporary test stimulation and, if effective, permanent implantation.

Device exampleInterStim system: an implantable system delivering chronic modulation of S3 (and occasionally S4) via a transforaminal route; includes lead placement and pulse generator.

IncludesPolicy explicitly includes test stimulation (percutaneous stimulation test) as part of the SNM process prior to permanent implantation.

Urethral bulking agents (UBA)

DefinitionUrethral bulking agents (UBA) are injectable periurethral substances used to increase tissue bulk and treat stress urinary incontinence, often used when surgery is contraindicated or declined.

FDA‑approved products

Policy Summary

PayerQualChoice

PolicyUrinary Incontinence Devices and Treatments

Policy CodePolicy CP.MP.142

Change TypeMaterial clinical and operational updates

Effective Date

Next Review Date

SourceLink

On This Page

This duration requirement appears in Criteria I.B. as a prerequisite for a trial of sacral neuromodulation with an FDA‑approved device.

Change noteCriteria I.B. was updated to shorten the urinary retention timing from 12 months to 6 months.

Incontinence reduction threshold

ThresholdPermanent SNM placement requires demonstration of at least a 50% reduction in incontinence symptoms (Criteria II.B.).

ScopeThe 'at least 50% reduction' wording was added/clarified in policy revisions to describe required symptomatic improvement prior to permanent implantation.

Associated criteriaThis reduction applies to incontinence, retention, or urgency/frequency as measured during percutaneous stimulation testing.

Urinary retention duration

Duration requirementFor urinary retention, symptoms must have been present for at least 6 months prior to consideration of SNM trial (Criteria I.B.).

Context of useThe 6‑month threshold applies where urinary retention contributes to the diagnosis of non‑obstructive urinary retention for SNM eligibility.

Revision noteThe policy updated the urinary retention timing from 12 months to 6 months in recent revisions.

Step Therapy

Document failure of required conservative therapies prior to trial/advanced therapy

Document prior conservative therapies before advanced interventions: for urgency/frequency or incontinence, bladder training, pelvic floor physical therapy with biofeedback, and pharmacologic treatment; for non‑obstructive urinary retention, intermittent self‑catheterization (unless not tolerated) and pharmacologic treatment.

Bladder training
Pelvic floor physical therapy with biofeedback
Pharmacologic therapy (appropriate medications)
Intermittent self‑catheterization for urinary retention when tolerated

Step Therapy

Progress through specified conservative measures before advanced therapy

Follow the policy progression of conservative measures (e.g., pelvic floor therapy replacing 'Kegel exercises') and ensure the member has undergone recommended conservative management prior to advanced treatments such as SNM or UBA.

Pelvic floor therapy, biofeedback, electrical stimulation as specified in Criteria III
Ensure conservative pathway is documented in the medical record

Documentation Required

Required documentation to support medical necessity

Include documentation that supports the diagnosis and eligibility for interventions: diagnosis (non‑obstructive urinary retention, overactive bladder, or persistent/recurrent stress urinary incontinence), symptom duration (≥6 months for SNM), failure of conservative therapies, and percutaneous test result (at least 50% improvement) prior to permanent SNM implantation.

Diagnosis and symptom history (duration ≥6 months when required)
Records of conservative treatments attempted and outcomes
Percutaneous stimulation test result showing ≥50% symptom reduction for permanent SNM

Documentation Required

Documentation and regulatory precedence — follow policy and applicable state/federal rules

Document medical necessity in accordance with this clinical policy and applicable coverage documents; where applicable, state Medicaid provisions and Medicare NCDs/LCDs take precedence and must be followed.

Maintain documentation consistent with policy criteria and Health Plan coverage documents
Comply with any controlling state or federal/regulatory requirements

Denial Risk

Denial risk: missing conservative therapy or insufficient test response

Failure to document prior conservative measures or to demonstrate at least a 50% reduction in symptoms on the percutaneous stimulation test prior to permanent SNM implantation may result in denial of coverage.

Lack of documented failure of conservative measures for urgency/frequency, incontinence, or retention
Percutaneous stimulation test result <50% symptom reduction before permanent SNM

Note

Coverage is conditional on contract terms, exclusions, and regulatory requirements

Coverage and authorization decisions are subject to the terms, exclusions, and limitations of the member's coverage documents and to applicable state and federal requirements; failure to follow those terms may result in denial or non‑payment.

Verify coverage under the member's specific policy and contractual terms
Apply state/federal requirements and Health Plan‑level administrative policies

Examples listed: Durasphere EXP (carbon-coated zirconium oxide beads in a gel), Macroplastique (crosslinked polydimethylsiloxane), Coaptite (calcium hydroxylapatite in gel), and Bulkamid (polyacrylamide hydrogel).

Clinical notesUBA therapy generally has lower long‑term efficacy than surgical options and often requires repeat injections; most common complications include urinary retention and urinary tract infection.

United States Food and Drug Administration (FDA) approved device

Definition'United States Food and Drug Administration (FDA) approved device' refers to a device that has received FDA approval and is specified in the policy as required for SNM trials and permanent SNM placement when indicated.

Policy usageThe policy requires use of an FDA‑approved device for SNM trials and includes language clarifying FDA approval in Criteria I and II.

Implication for prior authAdded policy language implies that device-related coverage and prior authorization decisions will reference FDA approval status per the criteria.